Medigene to present new pre-clinical data for pipeline TCR-T therapies at the ESMO Congress 2023
October 16, 2023 08:00 ET
|
Medigene AG
Planegg/Martinsried, October 16, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
October 15, 2023 18:05 ET
|
ImCheck Therapeutics SAS
ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety...
Explosive Growth in Dietary Supplements Underscores Relevance of New China E-commerce Market Data Report for Entrepreneurs
October 10, 2023 09:48 ET
|
Research and Markets
Dublin, Oct. 10, 2023 (GLOBE NEWSWIRE) -- In a time where health consciousness has never been more prevalent, the numbers say it all. According to the Institute of Medicine and National Research...
Single-Cell Omics Market revenue to hit USD 30 Billion by 2035, says Research Nester
October 03, 2023 06:09 ET
|
Research Nester
New York, Oct. 03, 2023 (GLOBE NEWSWIRE) -- The global single-cell omics market size is expected to expand at ~22% CAGR from 2023 to 2035. The market is anticipated to garner a revenue of USD 30...
Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein
September 27, 2023 08:00 ET
|
Medigene AG
Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
National Institute of Health to Fund Preclinical Development of Trethera Lead Drug, TRE-515, for Treatment of Crohn’s Disease
September 25, 2023 11:22 ET
|
Trethera Corporation
LOS ANGELES, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
Announcing the Olink® Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research.
September 19, 2023 03:00 ET
|
Olink Proteomics AB
Uppsala, Sweden, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Announcing the Olink® Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research. ...
Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
September 18, 2023 08:00 ET
|
Medigene AG
Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG to present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 11:00 ET
|
Medigene AG
Planegg/Martinsried, September 5, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for...
Globally Recognized Expert in Rare Neurologic Diseases, Dr. Michael Levy, Joins Trethera Scientific Advisory Board
September 05, 2023 10:55 ET
|
Trethera Corporation
LOS ANGELES, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...